The rise of GLP-1 drugs such as Ozempic and Mounjaro has been nothing short of meteoric. Originally developed to treat ...

Recent research reveals that metformin, a long-used diabetes drug, may function through the brain more than previously believed. Scientists found out that the medication reaches the ventromedial ...

DETROIT – Medications like Wegovy, Zepbound and Saxenda are revolutionizing weight loss for millions of Americans, but they are relatively new to the medical landscape. Large numbers of studies are ...

“Faster-acting drugs have a higher abuse potential,” said DiFeliceantonio. “They have a different impact on the brain. So if ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also cause pregnancy complications and harm some users. Weight-loss drugs are ...

GLP-1 receptor agonist medications have revolutionized weight management and diabetes treatment, offering significant benefits for millions of patients worldwide. However, these powerful medications ...

Ozempic (semaglutide) helps people with type 2 diabetes lower their blood sugar if diet, exercise, and other diabetes medications haven’t worked. If you’ve just gotten a prescription for it, you might ...

Share on Pinterest GLP-1 drugs may improve brain and heart health but could cause problems for the kidneys and pancreas, according to a new study. FreshSplash/Getty Images Researchers report that ...

New research reveals that popular GLP-1 medications like Ozempic could change how quickly alcohol affects the body, offering early clues into their surprising impact on craving, intoxication, and ...

Pancreatitis, vision loss ... the risks of drugs such as Ozempic can sound scary. But what does the evidence show?

OXFORD, Miss. – Cinnamon is one of the oldest and most commonly used spices in the world, but a new study from the National Center for Natural Products Research indicates a compound in it could ...

Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...